Envestnet Asset Management Inc Halozyme Therapeutics, Inc. Transaction History

Envestnet Asset Management Inc

$302 Billion
Q3 2024

A detailed history of Envestnet Asset Management Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 345,278 shares of HALO stock, worth $18.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

345,278

Previous 229,620 50.37%

Holding current value

$18.2 Million

Previous $12 Million 64.31%

% of portfolio

0.01%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$51.3 - $64.42 $5.93 Million - $7.45 Million	115,658 Added 50.37%	345,278 $19.8 Million
Q2 2024 Aug 08, 2024	BUY	$37.81 - $52.4 $402,714 - $558,112	10,651 Added 4.86%	229,620 $12 Million
Q1 2024 May 13, 2024	BUY	$33.68 - $41.95 $293,891 - $366,055	8,726 Added 4.15%	218,969 $8.91 Million
Q4 2023 Feb 13, 2024	SELL	$33.32 - $42.1 $171,997 - $217,320	-5,162 Reduced 2.4%	210,243 $7.77 Million
Q3 2023 Nov 13, 2023	BUY	$36.46 - $44.03 $2.67 Million - $3.23 Million	73,260 Added 51.54%	215,405 $8.23 Million
Q2 2023 Aug 04, 2023	SELL	$30.28 - $38.74 $4.54 Million - $5.81 Million	-149,871 Reduced 51.32%	142,145 $5.13 Million
Q1 2023 May 11, 2023	BUY	$32.86 - $55.7 $4.94 Million - $8.37 Million	150,218 Added 105.94%	292,016 $11.2 Million
Q4 2022 Feb 07, 2023	BUY	$40.06 - $59.44 $550,985 - $817,537	13,754 Added 10.74%	141,798 $8.07 Million
Q3 2022 Nov 10, 2022	BUY	$38.53 - $51.78 $2.23 Million - $2.99 Million	57,814 Added 82.32%	128,044 $5.06 Million
Q2 2022 Aug 03, 2022	BUY	$37.35 - $48.3 $207,367 - $268,161	5,552 Added 8.58%	70,230 $3.09 Million
Q1 2022 May 04, 2022	BUY	$31.97 - $41.06 $124,011 - $159,271	3,879 Added 6.38%	64,678 $2.58 Million
Q4 2021 Feb 04, 2022	SELL	$31.82 - $40.75 $2,895 - $3,708	-91 Reduced 0.15%	60,799 $2.45 Million
Q3 2021 Oct 07, 2021	BUY	$38.47 - $46.42 $548,966 - $662,413	14,270 Added 30.61%	60,890 $2.48 Million
Q2 2021 Aug 04, 2021	BUY	$38.84 - $51.31 $123,433 - $163,063	3,178 Added 7.32%	46,620 $2.12 Million
Q1 2021 May 04, 2021	BUY	$39.51 - $51.45 $623,033 - $811,315	15,769 Added 56.98%	43,442 $1.81 Million
Q4 2020 Feb 02, 2021	SELL	$25.81 - $43.62 $17,499 - $29,574	-678 Reduced 2.39%	27,673 $1.18 Million
Q3 2020 Oct 09, 2020	BUY	$25.74 - $29.63 $329,961 - $379,826	12,819 Added 82.53%	28,351 $745,000
Q2 2020 Jul 08, 2020	SELL	$16.25 - $26.81 $2,827 - $4,664	-174 Reduced 1.11%	15,532 $416,000
Q1 2020 Apr 23, 2020	BUY	$13.9 - $21.83 $9,674 - $15,193	696 Added 4.64%	15,706 $283,000
Q4 2019 Feb 11, 2020	BUY	$14.93 - $19.53 $9,361 - $12,245	627 Added 4.36%	15,010 $266,000
Q3 2019 Oct 17, 2019	BUY	$15.2 - $17.69 $5,228 - $6,085	344 Added 2.45%	14,383 $223,000
Q2 2019 Aug 02, 2019	BUY	$14.75 - $17.26 $4,130 - $4,832	280 Added 2.04%	14,039 $241,000
Q1 2019 May 10, 2019	SELL	$13.94 - $17.58 $59,858 - $75,488	-4,294 Reduced 23.79%	13,759 $222,000
Q4 2018 Feb 13, 2019	BUY	$13.33 - $18.66 $240,646 - $336,868	18,053 New	18,053 $264,000

Others Institutions Holding HALO

# of Institutions

542

Shares Held

125M

Call Options Held

294K

Put Options Held

180K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $7.35B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.

Account

Envestnet Asset Management Inc Halozyme Therapeutics, Inc. Transaction History